Insights

Scale-down models have become an increasingly common development tool, especially in the bioprocessing industry. Read our eBook to discover our approach to the challenge of scaling up scale down models.

Synthetic biology remains nascent, yet full of promise. The idea of using rational engineering approaches to design biology has the potential to solve some of humanity’s biggest challenges, such as securing food supplies...

In the world of bioprocessing engineering, companies developing cultured meat and other cultured ingredients face both technical and financial challenges at each step up in scale. Here, Steve Thomas and James Westley explain how sophisticated predictive models – digital twins – that couple biology, heat transfer, mass transfer and fluid dynamics can help… 

A meeting of minds - AI meets biology. This is the conversation that is bridging the gap between bioprocessing and machine learning.

The future of smart implantable medical devices – Our experts share key insights for medical implant manufacturers.

Being a woman in STEM is something I am proud of. Subjects such as science, technology, engineering, and mathematics (STEM) have always been a huge passion of mine – and so working at a company like Cambridge Consultants that has been at the forefront of innovative development for over 60 years is perfect for me.

Asia’s medical technology market is predicted to account for a third of global medical technology sales by 2025. As such, it's a hotbed for start-ups, so here are our six innovative start-ups to watch that are part of this year’s MedTech Innovator cohort. 

Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. It is a biomarker that Cell4D is using to screen and sort live cells

Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.

Founders of early-stage start-ups are characteristically passionate, driven and optimistic. Understandably so. Very often they are nurturing a breakthrough idea with the capacity to disrupt business and change the world for the better. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong. 

Yan Lin Lye and a team from CC are embarking on a sequence of mentoring sessions as part of our commitment to MedTech Innovator Asia Pacific. For the second consecutive year, we're collaborating with the organisation to provide hands-on professional support to selected start-up participants.

Access to advanced cell and gene therapies has been limited by their high cost. We've been looking at how AI can play a role in reducing the cost of manufacture of cell and gene therapies and hence make these treatments available to more patients.